Hypopharyngeal Cancer

Our multidisciplinary team has extensive experience in diagnosing and treating hypopharyngeal cancer, which develops in the hypopharynx, the bottom part of the throat. Our surgeons, medical oncologists, and radiation oncologists collaborate to create a treatment plan based on the location of the tumor, its size, and how far it has spread. The goal is to find the right combination of treatments to destroy hypopharyngeal cancer while preserving organ function.

Clinical Trials and Research Studies

Phase 5

First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

Learn More

Phase 2

A PHASE 2 STUDY OF ALKS 4230 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED OR RECURRENT HEAD AND NECK SQUAMOUS CELL CANCER CURRENTLY ON TREATENT WITH ANTI-PD-(L)1 WITHOUT HAVING ACHIEVED A COMPLETE REMISSION

Learn More

Phase 6

NRG-HN004 Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin.

Learn More

Phase -1

The AIM-HN and SEQ-HN Study: A 2 Cohort Non-comparative Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Learn More